Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC TAFUR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1679536387
CMS profile
30754
Location
LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$118.08

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $91.14 6
Education $26.94 3

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $26.94 3
Dova Pharmaceuticals $17.30 1
Incyte Corporation $17.24 1
Seagen Inc. $15.36 1
Astellas Pharma US Inc $14.30 1
Amgen Inc. $14.25 1
Rigel Pharmaceuticals, Inc. $12.69 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC TAFUR

NPI 1679536387 · CMS profile ID 30754

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679536387?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679536387?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679536387?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679536387?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $118.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Rigel Pharmaceuticals, Inc. $12.6911/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752090733 CMS
PFIZER INC. $10.7010/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743805003 CMS
PFIZER INC. $8.1209/09/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743311351 CMS
PFIZER INC. $8.1208/18/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743257659 CMS
Astellas Pharma US Inc $14.3003/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718388637 CMS
Incyte Corporation $17.2403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745812075 CMS
Dova Pharmaceuticals $17.3003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752351785 CMS
Seagen Inc. $15.3602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732453027 CMS
Amgen Inc. $14.2501/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741394735 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $828.42 56
PY2020 $118.08 9
PY2021 $138.59 9
PY2022 $11.97 1
PY2023 $96.84 6
PY2024 $472.12 20
PY2025 $636.04 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $24,700.00 2
PY2024 Principal investigator $850.00 2
PY2023 Principal investigator $16,152.90 11
PY2022 Principal investigator $75,305.83 35
PY2021 Principal investigator $57,088.81 68
PY2020 Principal investigator $164,987.76 78
PY2019 Principal investigator $218,143.35 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seattle Genetics, Inc. $14,000.00 12/04/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin LV for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 678821945
Principal investigator 1 PFIZER INC. $1,802.76 12/02/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671680473
Principal investigator 1 Exelixis Inc. $174.20 11/26/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687196243
Principal investigator 1 Exelixis Inc. $500.00 11/14/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687196539
Principal investigator 1 Ipsen Bioscience Inc $4,750.00 11/14/2019 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 643289361
Principal investigator 1 Incyte Corporation $74.62 11/08/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461391
Principal investigator 1 Incyte Corporation $42.84 11/08/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461393
Principal investigator 1 Incyte Corporation $71.42 11/08/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461395
Principal investigator 1 Incyte Corporation $13.92 11/08/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461397
Principal investigator 1 Incyte Corporation $14.00 11/08/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461399
Principal investigator 1 Incyte Corporation $1,003.24 11/07/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461381
Principal investigator 1 Incyte Corporation $531.10 11/07/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461383
Principal investigator 1 Incyte Corporation $130.77 11/07/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461385
Principal investigator 1 Incyte Corporation $57.66 11/07/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461387
Principal investigator 1 Incyte Corporation $249.70 11/07/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement No dispute reported 06/30/2026 666461389
Principal investigator 1 Seattle Genetics, Inc. $949.86 10/21/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821947
Principal investigator 1 PFIZER INC. $250.00 09/26/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671680415
Principal investigator 1 PFIZER INC. $7,419.77 09/24/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671680417
Principal investigator 1 Exelixis Inc. $174.20 09/10/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687198867
Principal investigator 1 Exelixis Inc. $1,939.62 09/10/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687198871
Principal investigator 1 Eli Lilly and Company $3,000.00 08/27/2019 Covered Recipient Teaching Hospital
COVENANT MEDICAL CENTER
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 No dispute reported 06/30/2026 654285133
Principal investigator 1 PFIZER INC. $750.00 08/27/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671680413
Principal investigator 1 Exelixis Inc. $1,002.96 08/20/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687197944
Principal investigator 1 Seattle Genetics, Inc. $500.00 08/14/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821907
Principal investigator 1 Exelixis Inc. $7,889.47 08/13/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687197949
Principal investigator 1 Ipsen Bioscience Inc $2,500.00 08/08/2019 Non-covered Recipient Entity
ST. JOSEPH HOSPITAL OF ORANGE
MM-398-07-02-03 No dispute reported 06/30/2026 643288725
Principal investigator 1 Eli Lilly and Company $2,500.00 08/06/2019 Covered Recipient Teaching Hospital
COVENANT MEDICAL CENTER
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION No dispute reported 06/30/2026 654285637
Principal investigator 1 Seattle Genetics, Inc. $633.24 07/16/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821909
Principal investigator 1 Exelixis Inc. $240.50 06/27/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199129
Principal investigator 1 Seattle Genetics, Inc. $224.00 06/26/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821891
Principal investigator 1 Seattle Genetics, Inc. $750.00 06/26/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821895
Principal investigator 1 Seattle Genetics, Inc. $224.00 06/26/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821899
Principal investigator 1 Exelixis Inc. $500.00 06/25/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687199095
Principal investigator 1 Ipsen Bioscience Inc $1,000.00 06/06/2019 Non-covered Recipient Entity
ST. JOSEPH HOSPITAL OF ORANGE
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 643288840
Principal investigator 1 Seattle Genetics, Inc. $2,500.00 05/29/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821889
Principal investigator 1 Seattle Genetics, Inc. $1,920.00 05/29/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821893
Principal investigator 1 PFIZER INC. $1,802.76 05/21/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634875
Principal investigator 1 PFIZER INC. $1,802.76 05/21/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634893
Principal investigator 1 PFIZER INC. $474.50 05/21/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634925
Principal investigator 1 PFIZER INC. $1,978.18 05/21/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634927
Principal investigator 1 Seattle Genetics, Inc. $35.97 05/15/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821887
Principal investigator 1 PFIZER INC. $1,971.66 05/09/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634895
Principal investigator 1 Seattle Genetics, Inc. $97.50 05/01/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821851
Principal investigator 1 Seattle Genetics, Inc. $36,413.38 04/18/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821885
Principal investigator 1 Eli Lilly and Company $2,223.30 04/09/2019 Non-covered Recipient Entity
METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION No dispute reported 06/30/2026 654290143
Principal investigator 1 PFIZER INC. $989.09 04/09/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634877
Principal investigator 1 PFIZER INC. $3,416.92 04/09/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671634879
Principal investigator 1 Exelixis Inc. $12,000.00 04/03/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
A Phase 1b Dose Escalation Study of Cabozantinib XL184 Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687197838
Principal investigator 1 Seattle Genetics, Inc. $668.96 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821865
Principal investigator 1 Seattle Genetics, Inc. $44.15 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821867
Principal investigator 1 Seattle Genetics, Inc. $861.39 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821873
Principal investigator 1 Seattle Genetics, Inc. $17.66 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821877
Principal investigator 1 Seattle Genetics, Inc. $162.50 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821879
Principal investigator 1 Seattle Genetics, Inc. $224.00 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821881
Principal investigator 1 Seattle Genetics, Inc. $240.32 04/03/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821883
Principal investigator 1 Seattle Genetics, Inc. $162.50 03/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821871
Principal investigator 1 Seattle Genetics, Inc. $25.00 03/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821875
Principal investigator 1 Seattle Genetics, Inc. $71.94 03/20/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821869
Principal investigator 1 Ipsen Bioscience Inc $2,500.00 03/07/2019 Non-covered Recipient Entity
ST. JOSEPH HOSPITAL OF ORANGE
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 643288565
Principal investigator 1 Exelixis Inc. $2,500.00 03/06/2019 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 687196999
Principal investigator 1 Seattle Genetics, Inc. $4,414.42 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821705
Principal investigator 1 Seattle Genetics, Inc. $232.83 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821731
Principal investigator 1 Seattle Genetics, Inc. $107.91 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821735
Principal investigator 1 Seattle Genetics, Inc. $100.00 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821737
Principal investigator 1 Seattle Genetics, Inc. $259.97 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821853
Principal investigator 1 Seattle Genetics, Inc. $100.00 03/06/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821897
Principal investigator 1 Ipsen Bioscience Inc $500.00 02/28/2019 Non-covered Recipient Entity
ST. JOSEPH HOSPITAL OF ORANGE
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 643288685
Principal investigator 1 Seattle Genetics, Inc. $18.41 02/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821723
Principal investigator 1 Seattle Genetics, Inc. $8.83 02/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821857
Principal investigator 1 Seattle Genetics, Inc. $250.24 02/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821859
Principal investigator 1 Seattle Genetics, Inc. $568.70 02/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821861
Principal investigator 1 Seattle Genetics, Inc. $25.00 02/27/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821863
Principal investigator 1 Seattle Genetics, Inc. $4,356.50 02/20/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821709
Principal investigator 1 Seattle Genetics, Inc. $833.26 02/20/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821717
Principal investigator 1 Seattle Genetics, Inc. $457.40 02/20/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821721
Principal investigator 1 Seattle Genetics, Inc. $35.32 02/13/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821733
Principal investigator 1 Seattle Genetics, Inc. $35.97 02/13/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821855
Principal investigator 1 PFIZER INC. $11,492.02 02/12/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671624693
Principal investigator 1 Seattle Genetics, Inc. $124.63 01/23/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821725
Principal investigator 1 Seattle Genetics, Inc. $50.00 01/23/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821729
Principal investigator 1 PFIZER INC. $500.00 01/22/2019 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 671626013
Principal investigator 1 Seattle Genetics, Inc. $50,921.40 01/18/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821715
Principal investigator 1 Eli Lilly and Company $613.70 01/15/2019 Non-covered Recipient Entity
METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 No dispute reported 06/30/2026 654295997
Principal investigator 1 Seattle Genetics, Inc. $224.00 01/09/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821707
Principal investigator 1 Seattle Genetics, Inc. $700.00 01/09/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821711
Principal investigator 1 Seattle Genetics, Inc. $7,713.76 01/09/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821713
Principal investigator 1 Seattle Genetics, Inc. $1,930.79 01/09/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821719
Principal investigator 1 Seattle Genetics, Inc. $600.00 01/09/2019 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678821727